New addition to Actavis’ diabetes portfolio: Repaglinide launched as patent expires
Actavis Group has launched Repaglinide tablets in the UK, Sweden and Hungary immediately after patent expiry. The product was launched simultaneously in Germany and will be launched in Italy and France in July. Repaglinide tablets have also been launched by an Italian customer of Medis, the Actavis subsidiary responsible for third-party sales.
Developed and produced by Actavis Malta, Repaglinide is used in the treatment of Type 2 diabetes and is the generic equivalent of the NovoNorm®/Prandin® brand by Novo Nordisk.
Sales of the originator product achieved EUR366.7m in 2010 (IMS Health, MIDAS MAT December 2010).
“Repaglinide is one of the most important oral anti-diabetics. We continue to intensify our focus on this therapeutic area and this product launch represents an important milestone in the development of our diabetes franchise,” said Lars Ramneborn, Executive Vice President of Europe Sales at Actavis.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.